MannKind files inhaled insulin Afresa in US
17 March 2009
Katie McQue
MannKindhas filed its rapid-acting insulin candidate, Afresa, in the US for the treatment of adults with types 1 and 2 diabetes.
"We are delighted to reach this important milestone," said the company's chairman and chief executive, Alfred Mann. "Afresa will be a first-in-class ultra rapid-acting...
Please Login to read the full article.
17 March 2009
Katie McQue
"We are delighted to reach this important milestone," said the company's chairman and chief executive, Alfred Mann. "Afresa will be a first-in-class ultra rapid-acting...
Please Login to read the full article.
RELATED CONTENT
NEWS
- Fox backs Civitas's Phase I trial of inhaled L-dopa Parkinson's candidate
- Not giving up on Afrezza, MannKind anticipates US FDA meeting to firm up trials
- Sanofi, Pfizer, Takeda, or Roche fit partner profile for Amylin's exenatide
- MannKind leaps 33% on FDA OK for Afrezza trials testing new inhaler
EVENTS
09 February 2012
London
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
